obesity and transplant outcomes in MM patients in the era of modern therapy, routine post-transplant maintenance, and genetic-based risk stratification. Methods: We retrospectively reviewed consecutive patients undergoing autoPBSCT for MM at our
Search Results
Zhubin J. Gahvari, Michael Lasarev, Jens C. Eickhoff, Aric C. Hall, Peiman Hematti, Mark B. Juckett, Vaishalee P. Kenkre, and Natalie S. Callander
Alexandra K. Zaleta, Shauna McManus, Joanne S. Buzaglo, Eva Y. N. Yuen, Julie S. Olson, Melissa F. Miller, Karen Hurley, Lillie D. Shockney, Sara Goldberger, Mitch Golant, and Kevin Stein
Background: Despite growing recognition that patient preferences and values should inform cancer care, patients’ views continue to be under-represented. We developed a quantitative tool, Valued Outcomes in the Cancer Experience (VOICE), to measure
Andrea Feldstain, Barry D. Bultz, Janet de Groot, Amane Abdul-Razzak, Leonie Herx, Lyle Galloway, Srini Chary, and Aynharan Sinnarajah
validated 12 – 15 ; however, it is considered a screening measure and not intended or appropriate for diagnostic purposes. Results in this study focus on outcomes regarding pain, fatigue, depression, anxiety, and well-being. Canadian Problem Checklist
Anthony A. Matthews, Sharon Peacock Hinton, Susannah Stanway, Alexander R. Lyon, Liam Smeeth, Krishnan Bhaskaran, and Jennifer L. Lund
focusing on composite cardiovascular outcomes. 4 – 13 Before attempting to fully understand the mechanisms behind changes in cardiovascular risk in women diagnosed with breast cancer, there is a pressing need for evidence on associations between breast
Daneng Li, Can-Lan Sun, Heeyoung Kim, Christiana Crook, Ya-Han Zhang, Rebecca Allen, Richard Ballena, Shadman Hyder, Marianna Koczywas, Vincent Chung, Dean Lim, Vani Katheria, William Dale, and Gagandeep Singh
and symptom relief, another study of older adults with solid tumors starting chemotherapy suggested that older adults may value other outcomes instead of survival. 11 The role of patient preferences in NETs has not yet been studied. Clinical trials
Zachary Veitch, Omar F. Khan, Derek Tilley, Domen Ribnikar, Xanthoula Kostaras, Karen King, Patricia Tang, and Sasha Lupichuk
-targeted therapies, such as trastuzumab. 3 – 5 However, outcomes for patients with HER2+ breast cancer treated outside of clinical trials are limited. 6 , 7 In small, node-negative, HER2+ tumors, the benefit of adding trastuzumab to adjuvant chemotherapy
Bin Wu and Lizheng Shi
gemcitabine-based chemotherapy, has significantly improved the outcome of patients with metastatic pancreatic cancer (MPC), increasing median overall survival (OS) to 8 to 12 months. 3 However, therapeutic options for MPC are still limited and the prognosis
Joseph A. Greer, Jamie M. Jacobs, Nicole Pensak, Lauren E. Nisotel, Joel N. Fishbein, James J. MacDonald, Molly E. Ream, Emily A. Walsh, Joanne Buzaglo, Alona Muzikansky, Inga T. Lennes, Steven A. Safren, William F. Pirl, and Jennifer S. Temel
survival. 10 – 14 Despite its importance for optimal outcomes, adherence to these medications varies widely, with rates ranging from as high as 100% to <50%. 15 – 18 A variety of patient-, clinician-, treatment-, and healthcare system–related factors are
Omar Abdel-Rahman, Hatim Karachiwala, and Jacob C. Easaw
potential of missing data or bias), and little attention to patients with advanced disease who received opioids for pain management rather than as a perioperative anesthetic. To provide a better assessment of the impact of opioid use on outcomes of patients
Christina Signorelli, Claire E. Wakefield, Karen A. Johnston, Joanna E. Fardell, Jordana K McLoone, Mary-Ellen E. Brierley, Maria Schaffer, Elysia Thornton-Benko, Afaf Girgis, W. Hamish Wallace, Richard J. Cohn, and on behalf of the BSU Implementation Group
increasingly recognized as key health professionals in survivorship care delivery, with preliminary evidence suggesting that nurse-led care is safe, acceptable, and feasible. 7 Specialized nurse practitioners have the potential to optimize patient outcomes by